Clinical trial
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ±…
NCT00389155 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00389155 |
|---|---|
| Title | First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy |
| Official title | A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Bladder Cancer, Transitional Cell Carcinoma, Metastasis |
| Intervention type | Drug, Other |
| Interventions | Vinflunine, Gemcitabine, Placebo |
| Enrollment | 34 |
| Start date | Jan 1, 2007 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2008 |
| First posted | Oct 18, 2006 |
| Last update posted | Dec 7, 2015 |
| Countries | Australia, Belgium, Canada, Denmark, France, Greece, Indonesia, Italy, Philippines, Poland, Russia, South Korea and 4 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: